Home

OrbiMed Israel GP Ltd.

CIK 1569590 · last filed 2026-04-09

OrbiMed Israel GP Ltd. is a corporate insider who has filed 17 SEC Form 4 insider transactions across 6 companies since 2017. The most recent filing shows the insider sold $5.4M of ACET on Apr 9, 2026. Across all open-market trades the lifetime net is −$47.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.4M across reported positions. The firm reports its address in Herzliya. 32 SEC filings were submitted jointly with OrbiMed Israel BioFund GP Limited Partnership.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.41M

Companies

6

Total Filings

17

Lifetime Open-Market Net

-$47.47M

Filer Profile

Reported Address
89 MEDINAT HAYEHUDIM STREET, 11TH FLOOR
HERZLIYA 46766
Phone
(212) 739-6400
State of Incorporation
Israel
Related Filers
OrbiMed Israel BioFund GP Limited Partnership — 32 joint filings, latest 2026-04-09
OrbiMed Advisors Israel II Ltd — 8 joint filings, latest 2026-04-09
OrbiMed Capital GP V LLC — 8 joint filings, latest 2026-04-09
OrbiMed Israel GP II, L.P. — 8 joint filings, latest 2026-04-09
ORBIMED ADVISORS LLC — 7 joint filings, latest 2026-04-09
OrbiMed Capital GP VI LLC — 7 joint filings, latest 2026-04-09
OrbiMed Genesis GP LLC — 5 joint filings, latest 2026-04-09
Erez Chimovits — 4 joint filings, latest 2024-05-20
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ACET Director 78,499 $9.52 $747.3K -$5.40M 2 2026-04-09
BiomX Inc. (PHGE.WS) Delisted Director 2,813,489 $0.01 $24.8K $242.5K 3 2021-07-30
9 METERS BIOPHARMA, INC. (NMTR) Delisted Director 1,597 $0.07 $115 -$41.87M 6 2021-06-25
CMMB 10%+ Owner 644,544 $2.58 $1.66M $0 1 2021-03-18
Eledon Pharmaceuticals, Inc. (NVUS) Delisted Director 73,650 — — -$451.8K 2 2020-12-04
Eledon Pharmaceuticals, Inc. (TKAI) Delisted Director 2,537,110 — — $0 1 2017-05-11

Recent Filings

17 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-04-09 ACET Sell (S) −837,264 -$5.40M EDGAR
2026-04-07 ACET Notice (144) −64,242 -$413.1K EDGAR
2024-09-12 — Notice (144) −500,000 -$1.01M EDGAR
2021-07-30 BiomX Inc. (PHGE.WS) Delisted Buy (P) +1,000,000 $0 EDGAR
2021-06-25 9 METERS BIOPHARMA, INC. (NMTR) Delisted Sell (S) −34,301,562 -$41.87M EDGAR
2021-05-13 9 METERS BIOPHARMA, INC. (NMTR) Delisted Exer (X) +63,888 $41.7K EDGAR
2021-03-19 9 METERS BIOPHARMA, INC. (NMTR) Delisted Mixed +37,860,510 $0 EDGAR
2021-03-18 CMMB Grant (A) +576,340 $10.00M EDGAR
2020-12-04 Eledon Pharmaceuticals, Inc. (NVUS) Delisted Sell (S) −206,400 -$4.46M EDGAR
2020-11-03 9 METERS BIOPHARMA, INC. (NMTR) Delisted Other (J) +3,887,468 $0 EDGAR
Showing 1–10 of 17
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.